NewAmsterdam Pharma Co N.V.
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
NAMS | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL00150012K9 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- GOOIMEER 2-35, NARRDEN
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
NewAmsterdam Pharma Co N.V. is a late-stage clinical biopharmaceutical company focused on improving care for patients with metabolic diseases where current therapies are insufficient or poorly tolerated. The company is developing treatments for cardiovascular disease (CVD) and other lipid-related conditions. Its lead candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. Obicetrapib is being investigated as a potent, cost-effective LDL-lowering therapy intended for use as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all NewAmsterdam Pharma Co N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NewAmsterdam Pharma Co N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NewAmsterdam Pharma Co N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
